Investor Relations 2021

Key Business Performance RemsimaⓇ & InflectraⓇ ✓ Infliximab market leader in major EU countries including EU5(market share 59%) ✓ Accelerating market share uptake in the US as Remicade® has been excluded from the United Healthcare's preferred drug list since Feb.2021 Market share of RemsimaⓇ/ InflectraⓇ in Europe Market share of InflectraⓇ in the US & RemsimaⓇ in Japan 100% 90% 80% 70% 60% 50% 15% 14% 11% 12% 10% 8% 9% 6% 5% 6% 4% 2% 3% 0% 59% 60% 57% 0% 54% 55% 52% 53% 17.1Q 3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.1Q 46% Inflectra® (US) 37% 20% 19% 40% 16% 28% 30% 18% 15% 12% 10% 20% 9% 10% 10% 8% 7% 6% 5% 4% 5% 3% 1% 0% 0% 15.2Q 4Q 16.2Q 4Q 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 16.1Q 3Q 17.1Q 3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.03 Remsima / Inflectra® Remicade Remsima® (Japan) Note: market share is based on volume Source: IQVIA Note: market share is based on volume Source: Symphony Health, IQVIA Investor Relations 2021 8

View entire presentation